MedPath

To investigate the optimal medical treatment after glaucoma surgery to achieve pressure drop in the eye.

Phase 1
Conditions
Medically uncontrolled glaucoma that requires filtration surgery.
MedDRA version: 20.0 Level: LLT Classification code 10018326 Term: Glaucoma NOS System Organ Class: 100000004853
Therapeutic area: Diseases [C] - Eye Diseases [C11]
Registration Number
EUCTR2018-001855-10-DK
Lead Sponsor
Department of Ophtalmology, Rigshospitalet-Glostrup
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Not specified
Target Recruitment
75
Inclusion Criteria

INCLUSION CRITERIA
•Patients with primary open-angle glaucoma (POAG), pseudoexfoliation syndrome (PEX), pigment dispersion syndrome (PDS) and ocular hypertension
•>50 years
•Women must be postmenopausal. Women are asked if they have menstruated within the preceding 12 months.
•Scheduled to undergo trabeculectomy surgery at the Department of Ophthalmology at Rigshospitalet-Glostrup, Denmark
•Only 1 eye can be included for each participant, but there are no restrictions as to whether it is the eye that undergoes surgery first or last. If both eyes of a participant are eligible, it will be decided by randomization which eye to be included in the study
•Informed consent to participation and ability to comply with study procedures

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 25
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

EXCLUSION CRITERIA
•Known allergy to any of the contents of the pharmaceuticals (active and in-active ingredients) used in the study
•Prior intraocular surgery, except from cataract surgery
•Medical history of anterior segment dysgenesis, inflammatory/uveitic glaucoma, angle closure glaucoma, neovascular glaucoma and traumatic glaucoma
•Steroid responders
•Pregnancy
•Fertile women, i.e. women who are not menopausal and women who breastfeed
•Patients who are excluded due to perioperative complications will not provide data for the study.
•Patients in systemic treatment with steroid or NSAID

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: The purpose of this study is to investigate which anti-inflammatory treatment provides better long-term control of intra-ocular pressure (IOP) following glaucoma surgery (trabeculectomy) by comparing topical NSAIDs to topical steroids or a combination of the two and to explore the mechanisms behind the pathophysiology of glaucoma. The primary outcome is the intraocular pressure 12 months after surgery measured by applanation tonometry.;Secondary Objective: Not applicable;Primary end point(s): The primary outcome is the intraocular pressure 12 months after surgery measured by applanation tonometry.;Timepoint(s) of evaluation of this end point: 12 months after surgery
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath